Last reviewed · How we verify

NCT06219018: HoneyForCINII

Effect of Honey For CIN II

Recruiting now Phase 1, PHASE2 Last updated 18 June 2025
What this trial tests

Phase 1, PHASE2 trial testing Medical grade honey formulation (MGH) (L-Mesitran®) in Cervical Intraepithelial Neoplasia-II in 60 participants. Currently enrolling.

Timeline
30 December 2024
Primary endpoint
1 December 2026
1 December 2027

Quick facts

Lead sponsorZuyderland Medisch Centrum
PhasePhase 1, PHASE2
StatusRecruiting now
Study typeINTERVENTIONAL
Allocationna
Designsingle group
Maskingnone
Primary purposetreatment
Enrollment60
Start date30 December 2024
Primary completion1 December 2026
Estimated completion1 December 2027
Sites2 locations across Netherlands

Drugs / interventions tested

Conditions studied

Sponsor

Zuyderland Medisch Centrum — full company profile →

Who can join

Adults 18 to 40, female only, with Cervical Intraepithelial Neoplasia-II or High Risk Human Papillomavirus. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The following hypothesis is tested: Medical grade honey in CIN II causes a higher clearance of the hr-HPV virus and an increase in the normalization of CIN II lesions compared to expectant management.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

  1. Effect of medical-grade honey (L-Mesitran) for cervical intraepithelial neoplasia II: protocol for a multicentre cohort pilot study (HONEY FOR CIN II study).
    Prop J, De Vos van Steenwijk P, Lardenoije CMJG, Cremers NAJ, et al · · 2025 · PMID 40707147 · DOI 10.1136/bmjopen-2025-104585

Verify or expand the search:

Other Zuyderland Medisch Centrum trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06219018.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing